Hologic Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hologic stock.
View analyst ratings for Hologic or view top-rated stocks.

Wall Street analysts have given Hologic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hologic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Hologic saw a decrease in short interest in the month of July. As of July 30th, there was short interest totaling 4,950,000 shares, a decrease of 19.5% from the July 15th total of 6,150,000 shares. Based on an average trading volume of 2,400,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 2.0% of the shares of the stock are sold short.
View Hologic's Short Interest.

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Hologic.

Hologic, Inc. (NASDAQ:HOLX) posted its earnings results on Wednesday, July, 28th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.12 by $0.21. The medical equipment provider earned $1.17 billion during the quarter, compared to the consensus estimate of $1.03 billion. Hologic had a net margin of 35.98% and a trailing twelve-month return on equity of 67.74%. During the same quarter in the previous year, the company earned $0.75 EPS.
View Hologic's earnings history.

Hologic's stock was trading at $43.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOLX stock has increased by 76.2% and is now trading at $77.15.
View which stocks have been most impacted by COVID-19.

Hologic updated its fourth quarter 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share (EPS) guidance of $0.920-$1.000 for the period, compared to the Thomson Reuters consensus estimate of $1.130. The company issued revenue guidance of $1 billion-$1.04 billion, compared to the consensus revenue estimate of $1.04 billion.

12 brokerages have issued 12-month price objectives for Hologic's stock. Their forecasts range from $75.00 to $100.00. On average, they expect Hologic's stock price to reach $86.93 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for Hologic or view top-rated stocks among Wall Street analysts.

283 employees have rated Hologic CEO Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among Hologic's employees.

Some companies that are related to Hologic include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Teleflex (TFX) and Abiomed (ABMD).
View all of HOLX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), The Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (14.80%), Vanguard Group Inc. (11.03%), BlackRock Inc. (8.49%), FMR LLC (5.95%), State Street Corp (4.34%) and Geode Capital Management LLC (2.12%). Company insiders that own Hologic stock include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty and Stephen P Macmillan.
View institutional ownership trends for Hologic.

HOLX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., Teacher Retirement System of Texas, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Sumitomo Mitsui Trust Holdings Inc., and Capula Management Ltd. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Kevin R Thornal, and Sean S Daugherty.
View insider buying and selling activity for Hologic or view top insider-selling stocks.

HOLX stock was bought by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Massachusetts Financial Services Co. MA, Parnassus Investments CA, Amundi, Vaughan Nelson Investment Management L.P., Armistice Capital LLC, AQR Capital Management LLC, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Hologic or or view top insider-buying stocks.

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOLX stock can currently be purchased for approximately $77.15.

Hologic has a market capitalization of $19.56 billion and generates $3.78 billion in revenue each year. The medical equipment provider earns $1.12 billion in net income (profit) each year or $3.98 on an earnings per share basis.

Hologic employs 5,814 workers across the globe.

The following companies are subsidiares of Hologic: Focal Therapeutics.

Hologic was founded in 1985.

The official website for Hologic is www.hologic.com.

Hologic is headquartered at 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at (508) 263-2900 or via email at [email protected]